Mechanisms for the Regulation of Phospholipase C Gene Expression in Cardiac Hypertrophy

Chapter

Abstract

Phospholipase C (PLC) is considered to mediate the cardiomyocyte hypertrophic response to norepinephrine. However, a paucity of information exists regarding the regulation of specific PLC isozyme gene and ­protein expression as well as activities in normal and hypertrophied myocardium. In this chapter, the role of PLC isozymes in cardiac hypertrophy as well as some of the mechanisms that are involved in the regulation of PLC isozyme gene expression, protein abundance and activities are discussed. On the basis of the available literature, it is suggested that specific PLC isozymes could be involved in the cardiomyocyte response to different hypertrophic stimuli and that modification of the transcriptional regulation of PLC isozymes could also prevent the progression of cardiac hypertrophy and its transition to heart failure.

Keywords

Phospholipase C Adult cardiomyocytes Signal transduction Regulation of gene expression Cardiac hypertrophy 

Notes

Acknowledgements

The work reported in this article was supported by the Heart and Stroke Foundation of Manitoba. Infrastructural support was provided by the St. Boniface Hospital Research Foundation.

References

  1. 1.
    Opie LH. The heart: physiology, from cell to circulation. 3rd ed. New York: Lippincott-Raven; 1998.Google Scholar
  2. 2.
    Lamers JM, De Jonge HW, Panagia V, et al. Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes. Cardioscience. 1993;4:121–31.PubMedGoogle Scholar
  3. 3.
    Izumo S, Aoki H. Calcineurin – the missing link in cardiac hypertrophy. Nat Med. 1998;4:661–2.PubMedCrossRefGoogle Scholar
  4. 4.
    Tappia PS, Singal T, Dent MR, et al. Phospholipid-mediated signaling in diseased myocardium. Future Lipidol. 2006;1:701–17.CrossRefGoogle Scholar
  5. 5.
    Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006;41:349–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Tappia PS. Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol. 2007;85:25–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. 2001;70:281–312.PubMedCrossRefGoogle Scholar
  8. 8.
    Singal T, Dhalla NS, Tappia PS. Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun. 2004;320:1015–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Singal T, Dhalla NS, Tappia PS. Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes. J Mol Cell Cardiol. 2006;41:126–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Tappia PS, Padua RR, Panagia V, et al. Fibroblast growth factor-2 stimulates phospholipase C β in adult cardiomyocytes. Biochem Cell Biol. 1999;77:569–75.PubMedCrossRefGoogle Scholar
  11. 11.
    Guo Y, Rebecchi M, Scariata S. Phospholipase C β2 binds to and inhibits phospholipase C δ1. J Biol Chem. 2005;280:1438–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Fukami K. Structure, regulation, and function of phospholipase C isozymes. J Biochem. 2002;131:293–9.PubMedGoogle Scholar
  13. 13.
    James SR, Downes CP. Structural and mechanistic features of phospholipases C: effectors of inositol phospholipid-mediated signal transduction. Cell Signal. 1997;9:329–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Lopez I, Mak EC, Ding J, et al. A novel bifunctional phospholipase C that is regulated by Gα12 and stimulates the Ras/mitogen-activated protein kinase pathway. J Biol Chem. 2001;276:2758–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Heredia Mdel P, Delgado C, Pereira L, et al. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol. 2005;38:205–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Balogh J, Wihlborg AK, Isackson H, et al. Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like ­receptors. J Mol Cell Cardiol. 2005;39:223–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Yin G, Yan C, Berk BC. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol. 2003;35:780–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Kockskämper J, Zima AV, Roderick HL, et al. Emerging roles of inositiol 1,4,5-trisphosphate signaling in cardiac myocytes. J Mol Cell Cardiol. 2008;45:128–47.PubMedCrossRefGoogle Scholar
  19. 19.
    Vasilevski O, Grubb DR, Filtz TM, et al. Ins(1,4,5)P3 regulates phospholipase C β1 expression in cardiomyocytes. J Mol Cell Cardiol. 2008;45:679–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu X, Zhang T, Bossuyt J, et al. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest. 2006;116:675–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205.PubMedCrossRefGoogle Scholar
  22. 22.
    Mackenzie L, Bootman MD, Laine M, et al. The role of inositol 1,4,5-trisphosphate receptors in Ca2+ signaling and the generation of arrhythmias in rat atrial myocytes. J Physiol. 2004;555:395–409.Google Scholar
  23. 23.
    Zima AV, Blatter LA. Inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in cat atrial excitation-­contraction coupling and arrhythmias. J Physiol. 2004;555:607–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Newton AC, Johnson JE. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta. 1998;1376:155–72.PubMedGoogle Scholar
  25. 25.
    Malhotra A, Kang BP, Opawumi D, et al. Molecular biology of protein kinase C signaling in cardiac myocytes. Mol Cell Biochem. 2001;225:97–107.PubMedCrossRefGoogle Scholar
  26. 26.
    Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res. 2000;87:1095–102.PubMedGoogle Scholar
  27. 27.
    Churchill E, Budas G, Vallentin A, et al. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol. 2008;48:569–99.PubMedCrossRefGoogle Scholar
  28. 28.
    Dorn 2nd GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527–37.PubMedGoogle Scholar
  29. 29.
    Sabri A, Steinberg SF. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem. 2003;251:97–101.PubMedCrossRefGoogle Scholar
  30. 30.
    Hodgkin MN, Pettitt TR, Martin A, et al. Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem Sci. 1998;23:200–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Pettitt TR, Martin A, Horton T, et al. Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells. J Biol Chem. 1997;272:17354–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev. 2000;80:1291–335.PubMedGoogle Scholar
  33. 33.
    Song C, Hu CD, Masago M, et al. Regulation of a novel human phospholipase C, PLCε, through membrane targeting by Ras. J Biol Chem. 2001;276:2752–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Saunders CM, Larman MG, Parrington J, et al. PLC ζ: a sperm-specific trigger of Ca2+ oscillations in eggs and embryo development. Development. 2002;129:3533–44.PubMedGoogle Scholar
  35. 35.
    Wing MR, Bourdon DM, Harden TK. PLC-ε: a shared effector protein in Ras-, Rho-, and G αβγ-mediated signaling. Mol Interv. 2003;3:273–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Hwang JI, Oh YS, Shin KJ, et al. Molecular cloning and characterization of a novel phospholipase C, PLC-η. Biochem J. 2005;389:181–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Tappia PS, Liu S-Y, Shatadal S, et al. Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am J Physiol. 1999;277:H40–9.PubMedGoogle Scholar
  38. 38.
    Wolf RA. Association of phospholipase C-δ with a highly enriched preparation of canine sarcolemma. Am J Physiol. 1992;263:C1021–8.PubMedGoogle Scholar
  39. 39.
    Wang H, Oestreich EA, Maekawa N, et al. Phospholipase C ε modulates β-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res. 2005;97:1305–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Asemu G, Dhalla NS, Tappia PS. Inhibition of PLC improves postischemic recovery in isolated rat heart. Am J Physiol Heart Circ Physiol. 2004;287:H2598–605.PubMedCrossRefGoogle Scholar
  41. 41.
    Kawaguchi H, Sano H, Iizuka K, et al. Phos­phati­dylinositol metabolism in hypertrophic rat heart. Circ Res. 1993;72:966–72.PubMedGoogle Scholar
  42. 42.
    Shoki M, Kawaguchi H, Okamoto H, et al. Phos­phatidylinositol and inositolphosphatide metabolism in hypertrophied rat heart. Jpn Circ J. 1992;56:142–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Sakata Y. Tissue factors contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO14.6): involvement of transforming growth factor-β1 and tissue renin-angiotensin system in the progression of cardiac hypertrophy. Hokkaido Igaku Zasshi. 1993;68:18–28.PubMedGoogle Scholar
  44. 44.
    Dent MR, Dhalla NS, Tappia PS. Phospholipase C gene expression, protein content and activities in cardiac hypertrophy and heart failure due to volume overload. Am J Physiol Heart Circ Physiol. 2004;282:H719–27.CrossRefGoogle Scholar
  45. 45.
    Dent MR, Aroutiounova N, Dhalla NS, et al. Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J Cell Mol Med. 2006;10:470–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Katan M. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim Biophys Acta. 1998;1436:5–17.PubMedGoogle Scholar
  47. 47.
    Jalili T, Takeishi Y, Song G, et al. PKC translocation without changes in Gαq and PLC-β protein abundance in cardiac hypertrophy and failure. Am J Physiol. 1999;277:H2298–304.PubMedGoogle Scholar
  48. 48.
    Giles TD, Sander GE, Thomas MG, et al. α-adrenergic mechanisms in the pathophysiology of left ventricular heart failure-An analysis of their role in systolic and diastolic dysfunction. J Mol Cell Cardiol. 1986;18:33–43.PubMedCrossRefGoogle Scholar
  49. 49.
    Prasad K, O’Neil CL, Bharadwaj B. Effect of ­prolonged prazosin treatment on hemodynamic and biochemical changes in the dog heart due to chronic pressure overload. Jpn Heart J. 1984;25:461–76.PubMedCrossRefGoogle Scholar
  50. 50.
    Motz W, Klepzig M, Strauer BE. Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol. 1987;10:S148–52.PubMedGoogle Scholar
  51. 51.
    Zakynthinos E, Pierrutsakos CH, Daniil Z, et al. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function. Angiology. 2005;56:439–49.PubMedCrossRefGoogle Scholar
  52. 52.
    Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol. 2004;43:380–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Ruzicka M, Yuan B, Leenen FH. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation. 2004;90:484–91.Google Scholar
  54. 54.
    Rothermund L, Vetter R, Dieterich M, et al. Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension. Circulation. 2002;106:2305–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Yamamoto K, Masuyama T, Sakata Y, et al. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens. 2002;20:753–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Lund AK, Goens MB, Nunez BA, et al. Characterizing the role of endothelin-1 in the progression of cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice. Toxicol Appl Pharmacol. 2006;212:127–35.PubMedCrossRefGoogle Scholar
  57. 57.
    Bai H, Wu LL, Xing DQ, et al. Angiotensin II induced upregulation of Gαq/11, phospholipase C β3 and extracellular signal-regulated kinase 1/2 via angiotensin II type 1 receptor. Chin Med J. 2004;117:88–93.PubMedGoogle Scholar
  58. 58.
    Lamers JM, Eskildsen-Helmond YE, Resink AM, et al. Endothelin-1-induced phospholipase C-β and D and protein kinase C isoenzyme in signaling leading to hypertrophy in rat cardiomyocytes. J Cardiovasc Pharmacol. 1995;26:S100–3.PubMedGoogle Scholar
  59. 59.
    Schnabel P, Mies F, Nohr T, et al. Differential regulation of phospholipase C-β isozymes in cardiomyocyte hypertrophy. Biochem Biophys Res Commun. 2000;275:1–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Otaegui D, Querejeta R, Arrieta A, et al. Phospholipase C β4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes. Mol Cell Biochem. 2010;337:167–73.PubMedCrossRefGoogle Scholar
  61. 61.
    Nagata S. Apoptosis by death factor. Cell. 1997;88:355–65.PubMedCrossRefGoogle Scholar
  62. 62.
    Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 β and induces cardiac hypertrophy following pressure overload. J Clin Invest. 2002;109:373–81.PubMedGoogle Scholar
  63. 63.
    Barac YD, Zeevi-Levin N, Yaniv G, et al. The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res. 2005;68:75–86.PubMedCrossRefGoogle Scholar
  64. 64.
    Ruwhof C, van Wamel JT, Noordzij LA, et al. Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal cardiomyocytes. Cell Calcium. 2001;29:73–83.PubMedCrossRefGoogle Scholar
  65. 65.
    D’Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA. 1997;94:8121–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Sakata Y, Hoit BD, Liggett SB, et al. Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation. 1998;97:1488–95.PubMedGoogle Scholar
  67. 67.
    Adams JW, Sakata Y, Davis MG, et al. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA. 1998;95:10140–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Sussman MA, Welch S, Walker A, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest. 2000;105:875–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA. 2000;97:931–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Mende U, Kagen A, Cohen A, et al. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA. 1998;95:13893–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Mende U, Kagen A, Meister M, et al. Signal transduction in atria and ventricles of mice with transient cardiac expression of activated G protein αq. Circ Res. 1999;85:1085–91.PubMedGoogle Scholar
  72. 72.
    Mende U, Semsarian C, Martins DC, et al. Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein αq: lack of correlation between phospholipase C activation and the phenotype. J Mol Cell Cardiol. 2001;33:1477–91.PubMedCrossRefGoogle Scholar
  73. 73.
    Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev. 2002;54:527–59.PubMedCrossRefGoogle Scholar
  74. 74.
    Anger T, Zhang W, Mende U. Differential contribution of GTPase activation and effector antagonism to the inhibitory effect of RGS proteins on Gq-mediated signaling in vivo. J Biol Chem. 2004;279:3906–15.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang W, Anger T, Su J, et al. Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem. 2006;281:5811–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Lin F, Owens WA, Chen S, et al. Targeted α1B-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res. 2001;89:343–50.PubMedCrossRefGoogle Scholar
  77. 77.
    Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active 1β-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA. 1994;91:10109–13.PubMedCrossRefGoogle Scholar
  78. 78.
    Heemskerk JWM, Farndale RW, Sage SO. Effects of U73122 and U73343 on human platelet calcium ­signalling and protein tyrosine phosphorylation. Biochim Biophys Acta. 1997;1355:81–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Jin W, Lo TM, Loh HH, et al. U73122 inhibits phospholipase C-dependent calcium mobilization in ­neuronal cells. Brain Res. 1994;642:237–43.PubMedCrossRefGoogle Scholar
  80. 80.
    Mogami H, Mills CL, Gallagher DV. Phospholipase C inhibitor, U73122, releases intracellular Ca2+, potentiates Ins(1,4,5)P-3-mediated Ca2+ release and directly activates inn channels in mouse pancreatic acinar cells. Biochem J. 1997;324:645–51.PubMedGoogle Scholar
  81. 81.
    Muto Y, Nagao T, Urushidani T. The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. J Pharmacol Exp Ther. 1997;282:1379–88.PubMedGoogle Scholar
  82. 82.
    Berven LA, Barritt GJ. Evidence obtained using single hepatocytes for inhibition by the phospholipase C inhibitor U73122 of store-operated Ca2+ inflow. Biochem Pharmacol. 1995;49:1373–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Arthur JF, Matkovich SJ, Mitchell CJ, et al. Evidence for selective coupling of α1-adrenergic receptors to phospholipase C-β1 in rat neonatal cardiomyocytes. J Biol Chem. 2001;276:37341–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Grubb DR, Vasilevski O, Huynh H, et al. The extreme C-terminal region of phospholipase C β1 determines subcellular localization and function; the “b” splice variant mediates α1- adrenergic receptor responses in cardiomyocytes. FASEB J. 2008;22:2768–74.PubMedCrossRefGoogle Scholar
  85. 85.
    Morris JB, Huynh H, Vasilevski O, et al. α1-Adrenergic receptor signaling is localized to caveolae in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2006;41:117–25.CrossRefGoogle Scholar
  86. 86.
    Filtz TM, Grubb DR, McLeod-Dryden TJ, et al. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cβ1b. FASEB J. 2009;23:3564–70.PubMedCrossRefGoogle Scholar
  87. 87.
    Barka T, van der Noen H, Shaw PA. Proto-oncogene fos (c-fos) expression in the heart. Oncogene. 1987;1:439–43.PubMedGoogle Scholar
  88. 88.
    Hannan RD, West AK. Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. Basic Res Cardiol. 1991;86:154–64.PubMedCrossRefGoogle Scholar
  89. 89.
    Iwaki K, Sukhatme VP, Shubeita HE, et al. α- and β-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an α1-mediated response. J Biol Chem. 1990;265:13809–17.PubMedGoogle Scholar
  90. 90.
    Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem. 1990;265:3595–8.PubMedGoogle Scholar
  91. 91.
    Hefti MA, Harder BA, Eppenberger HM, et al. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 1997;29:2873–92.PubMedCrossRefGoogle Scholar
  92. 92.
    Chiu R, Boyle WJ, Meek J, et al. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 1988;54:541–52.PubMedCrossRefGoogle Scholar
  93. 93.
    Lijnen P, Petrov V. Antagonism of the re1nin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Methods Fund Exp Clin Pharmacol. 1999;21:363–74.CrossRefGoogle Scholar
  94. 94.
    Omura T, Yoshiyama M, Yoshida K, et al. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension. 2002;39:81–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Singal T, Dhalla NS, Tappia PS. Reciprocal regulation of transcription factors and PLC isozyme gene expression in adult cardiomyocytes. J Cell Mol Med. 2010;14:1824–35.PubMedCrossRefGoogle Scholar
  96. 96.
    Singal T, Dhalla NS, Tappia PS. Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes. Mol Cell Biochem. 2009;327:229–39.PubMedCrossRefGoogle Scholar
  97. 97.
    Dhalla NS, Xu Y-J, Sheu S-S, et al. Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol. 1997;29:2865–71.PubMedCrossRefGoogle Scholar
  98. 98.
    Small K, Feng JF, Lorenz J, et al. Cardiac specific overexpression of transglutaminase II (Gh) results in a unique hypertrophy phenotype independent of phospholipase C activation. J Biol Chem. 1999;23:21291–6.CrossRefGoogle Scholar
  99. 99.
    Tappia PS, Yu CH, Di Nardo P, et al. Depressed responsiveness of phospholipase C isoenzymes to phosphatidic acid in congestive heart failure. J Mol Cell Cardiol. 2001;33:431–40.PubMedCrossRefGoogle Scholar
  100. 100.
    Henry RA, Boyce SY, Kurz T, et al. Stimulation and binding of myocardial phospholipase C by phosphatidic acid. Am J Physiol. 1995;269:C349–58.PubMedGoogle Scholar
  101. 101.
    Tappia PS, Singal T. Regulation of phospholipase C in cardiac hypertrophy. Clin Lipidol. 2009;4:79–90.CrossRefGoogle Scholar
  102. 102.
    Peivandi AA, Huhn A, Lehr HA, et al. Upregulation of phospholipase D expression and activation in ventricular pressure-overload hypertrophy. J Pharmacol Sci. 2005;98:244–54.PubMedCrossRefGoogle Scholar
  103. 103.
    Eskildsen-Helmond YE, Bezstarosti K, Dekkers DH, et al. Cross-talk between receptor-mediated phospholipase C-β and D via protein kinase C as intracellular signal possibly leading to hypertrophy in serum-free cultured cardiomyocytes. J Mol Cell Cardiol. 1997;29:2545–59.PubMedCrossRefGoogle Scholar
  104. 104.
    Murthy SN, Chung PH, Lin L, et al. Activation of phospholipase Cε by free fatty acids and cross talk with phospholipase D and phospholipase A2. Biochemistry. 2006;45:10987–97.PubMedCrossRefGoogle Scholar
  105. 105.
    Liu SY, Tappia PS, Dai J, et al. Phospholipase A2-mediated activation of phospholipase D in rat heart sarcolemma. J Mol Cell Cardiol. 1998;30:1203–14.PubMedCrossRefGoogle Scholar
  106. 106.
    Strauer BE, Bayer F, Brecht HM, et al. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens. 1985;3:S39–44.CrossRefGoogle Scholar
  107. 107.
    Strauer BE. Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects. Z Kardiol. 1995;74:171–8.Google Scholar
  108. 108.
    Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol. 1988;12:S45–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Asper Clinical Research Institute, St. Boniface Hospital Research and Department of Human Nutritional SciencesWinnipegCanada

Personalised recommendations